Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Michael Stocum to Step Down as Inivata CEO
Search for new CEO is underway
Research Triangle Park, NC and Cambridge, UK, May 8, 2018 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care announces that Michael Stocum has stepped down as CEO to pursue other interests.
Michael Stocum said, "It has been a privilege leading Inivata as we grew from an academic spinout to our current stage of development over the past four years. The company is now entering its next stage of growth with an increasing focus on commercialisation and needs a CEO with a different set of skills."
Jeff Buchalter, Chairman, said, "I would like to thank Mike for his significant contribution to Inivata and wish him well in his future endeavours. Inivata has developed a highly-sensitive liquid biopsy platform that positions it strongly in a fast-growing market. I look forward to the next phase of the Company's development with considerable confidence."
The Company has initiated a search for a new CEO.
About Inivata
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care. Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies. The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton
[email protected] +44 (0)20 3709 5700
Karen Chandler-Smith
[email protected] +44 (0)7900 430235
